


# Mass drug administration for falciparum malaria



A practical field manual




World Health  
Organization



# Mass drug administration for falciparum malaria



A practical field manual





# Contents

<b>Acknowledgements</b>	<b>vii</b>
<b>Abbreviations and acronyms</b>	<b>viii</b>
<b>Executive summary</b>	<b>ix</b>
<b>1. INTRODUCTION</b>	<b>1</b>
1.1 Background	1
1.2 Definitions	1
1.3 Objective	1
1.4 WHO recommendations	2
<b>2. ORGANIZATION AND IMPLEMENTATION</b>	
<b>2.1 Design phase (macroplanning)</b>	<b>3</b>
2.1.1 Identify agencies to support the ministry of health	3
2.1.2 Establish a task force or coordinating committee	4
2.1.3 Conduct a context analysis	6
2.1.4 Determine the target population and geographical areas	7
2.1.5 Choose the antimalarial medicine	10
2.1.6 Estimate the requirement for antimalarial medicine, and order it	13
2.1.7 Determine the delivery strategy	13
2.1.8 Determine the period of intervention	14
2.1.9 Determine the number of rounds	15
2.1.10 Establish a chronogram	17
2.1.11 Draw up a budget	17
<b>2.2 Planning and preparation</b>	<b>18</b>
2.2.1 Micro-planning	18
2.2.2 Logistics	20
2.2.3 Human resources	22
2.2.4 Community engagement, social mobilization and communication	26
<b>2.3 Implementation</b>	<b>32</b>
2.3.1 Stock management	32
2.3.2 Distribution of antimalarial medicine	34
2.3.3 Supervision	37
2.3.4 Data collection	39

2.3.5 Coordination	42
2.3.6 Treatment of malaria cases after mass drug administration	43
<b>3. MONITORING AND EVALUATION</b>	<b>44</b>
<b>3.1 Monitoring system</b>	<b>44</b>
<b>3.2 Estimate of coverage</b>	<b>44</b>
3.2.1 Distribution coverage	44
3.2.2 Post-MDA campaign survey	46
<b>3.3 Monitoring consumption</b>	<b>46</b>
<b>3.4 Pharmacovigilance</b>	<b>47</b>
3.4.1 Definitions	48
3.4.2 Safety communication	49
3.4.3 Surveillance of adverse drug reactions	49
<b>3.5 Monitoring drug resistance</b>	<b>50</b>
<b>3.6 Evaluating impact</b>	<b>51</b>
<b>4. REPORTING</b>	<b>53</b>
<b>5. KEY STEPS IN A MASS DRUG ADMINISTRATION CAMPAIGN FOR MALARIA</b>	<b>55</b>
<b>REFERENCES</b>	<b>56</b>
<b>ANNEXES</b>	<b>59</b>
<b>Annex 1</b> – Standard distribution of populations in a developing country	59
<b>Annex 2</b> – Available artemisinin-based combination therapy: dosing, formulation and presentation	60
<b>Annex 3</b> – Example of calculation of orders for antimalarial medicine	66
<b>Annex 4</b> – Example of a chronogram for mass drug administration for malaria (distribution at 8 weeks)	69
<b>Annex 5</b> – Example of micro-planning in urban Western Area, Sierra Leone	72
<b>Annex 6</b> – Step-by-step procedure for prepositioning supplies	75
<b>Annex 7</b> – Example of radio spot on MDA for malaria (used in Sierra Leone in 2014–2015)	76
<b>Annex 8</b> – Examples of discussion points on MDA for use at community meetings (adapted from those used in Sierra Leone in 2014–2015)	77

<b>Annex 9</b> - Household visit for MDA, step by step	78
<b>Annex 10</b> - Algorithm to assist community health workers in applying exclusion criteria	79
<b>Annex 11</b> - Algorithm for determining the pregnancy status of women of reproductive age (15–49 years) (based on and adapted from algorithms used in malaria MDA in Mozambique by the Centro de Investigação em Saúde de Manhiça)	80
<b>Annex 12</b> - Example of laminated leaflet used by community health workers in Sierra Leone in 2014–2015 to explain treatment dosage	81
<b>Annex 13</b> - Example of tally sheet (adapted from that used in Sierra Leone in 2014–2015)	82
<b>Annex 14</b> - Example of a household registration form (adapted from the Zambia MDA programme delivery handbook)	83
<b>Annex 15</b> - Example of supervisors' checklist used in Sierra Leone in 2014–2015	84
<b>Annex 16</b> - Example of MDA Card	85
<b>Annex 17</b> - Example of daily summary sheet to be completed by distribution team supervisors (adapted from that used in Sierra Leone in 2014–2015)	86
<b>Annex 18</b> - Example of database for data compilation (used in Sierra Leone in 2014–2015)	87
<b>Annex 19</b> - Example of standard template for reporting a suspected adverse drug reaction	89
<b>Annex 20</b> - Example of questionnaire for post-MDA survey	92
<b>Annex 21</b> - Example of pharmacovigilance preparedness checklist (used in Sierra Leone in 2014–2015)	96
<b>Annex 22</b> - Example of an MDA pharmacovigilance training module	97

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_26246](https://www.yunbaogao.cn/report/index/report?reportId=5_26246)

